Financial Data and Key Metrics Changes - Revenue for Q4 2025 was EUR 248 million, with full-year 2025 revenue totaling EUR 720 million, reflecting strong growth compared to previous periods [20][21] - Operating profit for Q4 2025 was EUR 10 million, with operating cash flow of EUR 73 million [21] - The company ended 2025 with EUR 616 million in cash and cash equivalents, up from EUR 560 million at the end of 2024 [21] Business Line Data and Key Metrics Changes - Europats revenue for Q4 2025 was EUR 187 million, bringing full-year revenue to EUR 477 million, with a significant increase from EUR 140 million in Q3 2025 [20][8] - SKYTROFA generated EUR 53 million in Q4 2025, totaling EUR 206 million for the full year [20][10] - The overall insurance approval rate for Europats in the U.S. is approximately 70%, with expectations for continued growth as more patients initiate treatment [8][24] Market Data and Key Metrics Changes - In the U.S., more than 5,300 patients were prescribed Europats by nearly 2,400 unique healthcare providers, indicating strong demand [8] - Europats is now available commercially in over 30 countries, with full commercial reimbursement in four European countries and two international markets [9] - The company expects full commercial launches in 10 additional countries in 2026 [9] Company Strategy and Development Direction - The company aims to achieve operating cash flow of around EUR 500 million in 2026 and at least EUR 5 billion in annual product revenue by 2030, as part of its Vision 2030 strategy [6][18] - There is a focus on expanding the pipeline of blockbuster product opportunities and enhancing the commercial infrastructure [6][17] - The company plans to continue investing in label expansion for current products and developing new products in both rare endocrine diseases and other therapeutic areas [16][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of Europats and SKYTROFA, highlighting the strong clinical value proposition and the ongoing expansion of treatment options [24][32] - The company is optimistic about the upcoming approval of TransCon CNP and its potential impact on revenue growth [36][45] - Management acknowledged the competitive landscape but emphasized the unique benefits of their hormone replacement therapies compared to emerging agents [59] Other Important Information - TransCon Growth Hormone (SKYTROFA) is approved for both pediatric and adult growth hormone deficiency, with ongoing trials to expand its indications [10][12] - The company is advancing its once-weekly TransCon PTH candidate, which is expected to enter the clinic soon [51] - The collaboration with Novo Nordisk for once-monthly TransCon Semaglutide is progressing towards clinical trials [17][56] Q&A Session Summary Question: Confidence level heading into the TransCon CNP PDUFA - Management expressed high confidence in the approval of TransCon CNP, similar to previous product approvals [23] Question: Insurance approval rate for Europat - Management is satisfied with the current 70% approval rate and noted that reaching 100% is unlikely due to natural filtering processes [24][26] Question: Europat pricing and net pricing trends - Management refrained from discussing net pricing but indicated a focus on revenue growth moving forward [29] Question: Patient enrollment for Europat - Management confirmed that they will focus more on revenue reporting as the product matures in the market [30] Question: Competitive landscape for hypoparathyroidism treatments - Management criticized emerging agents like Encaleret, emphasizing the unique benefits of their hormone replacement therapy [59]